SE0402221D0 - Treatment of insufficient perfusion - Google Patents
Treatment of insufficient perfusionInfo
- Publication number
- SE0402221D0 SE0402221D0 SE0402221A SE0402221A SE0402221D0 SE 0402221 D0 SE0402221 D0 SE 0402221D0 SE 0402221 A SE0402221 A SE 0402221A SE 0402221 A SE0402221 A SE 0402221A SE 0402221 D0 SE0402221 D0 SE 0402221D0
- Authority
- SE
- Sweden
- Prior art keywords
- treatment
- insufficient perfusion
- composition
- perfusion
- insufficient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0402221A SE0402221D0 (sv) | 2004-09-14 | 2004-09-14 | Treatment of insufficient perfusion |
EP05783432A EP1789060A1 (en) | 2004-09-14 | 2005-09-14 | Compositions comprising compounds capable of forming a reversible bond or association with gaseous nitric oxide |
US10/573,335 US8552068B2 (en) | 2004-09-14 | 2005-09-14 | Compositions and methods |
PCT/SE2005/001336 WO2006031191A1 (en) | 2004-09-14 | 2005-09-14 | Compositions comprising compounds capable of forming a reversible bond or association with gaseous nitric oxide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0402221A SE0402221D0 (sv) | 2004-09-14 | 2004-09-14 | Treatment of insufficient perfusion |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0402221D0 true SE0402221D0 (sv) | 2004-09-14 |
Family
ID=33157545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0402221A SE0402221D0 (sv) | 2004-09-14 | 2004-09-14 | Treatment of insufficient perfusion |
Country Status (4)
Country | Link |
---|---|
US (1) | US8552068B2 (sv) |
EP (1) | EP1789060A1 (sv) |
SE (1) | SE0402221D0 (sv) |
WO (1) | WO2006031191A1 (sv) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0613856D0 (en) * | 2006-07-13 | 2006-08-23 | Isis Innovation | Method for reducing spasms |
US20080146579A1 (en) * | 2006-12-15 | 2008-06-19 | N.V. Nutricia | Treatment of patients with chronic pulmonary diseases and nutritional compositions therefore |
CN101835502A (zh) | 2007-09-21 | 2010-09-15 | 伊诺克斯生物制药公司 | 释放抗微生物气体的耳引流管 |
WO2012153331A2 (en) * | 2011-05-09 | 2012-11-15 | Topical Therapeutic Agent (Tta) Ltd. | Nitric oxide-sequestering topical formulations |
CA2874807C (en) * | 2012-05-29 | 2022-06-07 | Neozyme International, Inc. | Process for treating organic material |
US10681914B2 (en) | 2012-05-29 | 2020-06-16 | Neozyme International, Inc. | Non-toxic plant agent compositions and methods and uses thereof |
US10334856B2 (en) | 2012-05-29 | 2019-07-02 | Neozyme International, Inc. | Non-toxic pest control compositions and methods and uses thereof |
US10557234B2 (en) | 2012-05-29 | 2020-02-11 | Neozyme International, Inc. | Papermaking additive compositions and methods and uses thereof |
US11193077B1 (en) | 2013-03-13 | 2021-12-07 | Airworthy Autogas, Llc | Gasoline for aircraft use |
GB2579240B (en) | 2018-11-27 | 2020-12-16 | Attgeno Ab | New processes, compositions and medical uses |
GB202007929D0 (en) | 2020-05-27 | 2020-07-08 | Attgeno Ab | New medical uses |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE468416B (sv) | 1991-09-27 | 1993-01-18 | Lars Erik Gustafsson | Saett att faststaella aktuell lungfunktion samt anordning foer att indikera naemnda lungfunktion |
EP1025853A3 (en) * | 1991-11-14 | 2000-11-08 | Brigham And Women's Hospital | Pharmaceutical composition containing S-nitroso-heme proteins and use thereof |
US5646181A (en) * | 1992-07-02 | 1997-07-08 | Research Foundation Of State University Of New York | Method and compositions for treating impotence |
WO1994016740A1 (en) | 1993-01-29 | 1994-08-04 | Brigham And Women's Hospital | The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury |
WO1994022482A1 (en) | 1993-03-26 | 1994-10-13 | Biorelease Technologies, Inc. | Compositions including heme-containing proteins and methods relating thereto |
JP3248533B2 (ja) | 1993-07-06 | 2002-01-21 | アエロクライン・アクチボラゲット | 呼気中のnoレベルの測定に使用されるシステムおよび異常noレベルに関連する疾患の診断方法 |
US6087479A (en) * | 1993-09-17 | 2000-07-11 | Nitromed, Inc. | Localized use of nitric oxide-adducts to prevent internal tissue damage |
US6255277B1 (en) | 1993-09-17 | 2001-07-03 | Brigham And Women's Hospital | Localized use of nitric oxide-adducts to prevent internal tissue damage |
ES2167608T3 (es) | 1995-10-20 | 2002-05-16 | L Air Liquide S A Directoire E | Composicion basada en monoxido de nitrogeno como medicamento. |
US6294517B1 (en) * | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
US20020061879A1 (en) * | 1996-02-02 | 2002-05-23 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
DE19654895C2 (de) | 1996-02-07 | 2000-07-27 | Sanol Arznei Schwarz Gmbh | Detektionsverfahren |
US6232434B1 (en) * | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
AU3877800A (en) * | 1999-03-30 | 2000-10-16 | Trustees Of Boston University | Compositions and methods for producing platelets and/or proplatelets from megakaryocytes |
US6737447B1 (en) * | 1999-10-08 | 2004-05-18 | The University Of Akron | Nitric oxide-modified linear poly(ethylenimine) fibers and uses thereof |
US6762202B2 (en) * | 2000-05-09 | 2004-07-13 | Nitromed, Inc. | Infrared thermography and methods of use |
WO2001089519A1 (en) * | 2000-05-22 | 2001-11-29 | Nitromed, Inc. | Thromboxane inhibitors, compositions and methods of use related applications |
US6706274B2 (en) * | 2001-01-18 | 2004-03-16 | Scimed Life Systems, Inc. | Differential delivery of nitric oxide |
US6673338B1 (en) * | 2001-09-10 | 2004-01-06 | The United States Of America As Represented By The Department Of Health And Human Services | Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same |
US7767232B2 (en) * | 2002-09-19 | 2010-08-03 | New York University | Control of nitric oxide bioactivity by perfluorocarbons |
-
2004
- 2004-09-14 SE SE0402221A patent/SE0402221D0/sv unknown
-
2005
- 2005-09-14 WO PCT/SE2005/001336 patent/WO2006031191A1/en active Application Filing
- 2005-09-14 US US10/573,335 patent/US8552068B2/en active Active
- 2005-09-14 EP EP05783432A patent/EP1789060A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2006031191A8 (en) | 2006-12-28 |
WO2006031191A1 (en) | 2006-03-23 |
US20080293813A1 (en) | 2008-11-27 |
EP1789060A1 (en) | 2007-05-30 |
US8552068B2 (en) | 2013-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA88464C2 (ru) | Способ дермального введения метадоновой композиции с обеспечением системного действия | |
DK1853250T3 (da) | Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi | |
WO2013061083A3 (en) | Therapeutic agents and uses thereof | |
UY27720A1 (es) | Aroilpiridinonas monocíclicas, | |
TW200626558A (en) | Indazolone derivatives | |
TW200531702A (en) | Pharmaceutical preparation comprising an antibody against the egf receptor | |
MX2010010954A (es) | Farmaco contra cancer de higado. | |
NO20080068L (no) | Topisk unguale formuleringer | |
BRPI0806531A2 (pt) | Composto, composição farmacêutica, agente terapêutico, e, uso do composto. | |
MX2007000979A (es) | Tratamiento de la hipertension pulmonar por iloprost inhalado con una formulacion microparticulada. | |
WO2006031191A8 (en) | Compositions comprising compounds capable of forming a reversible bond or association with gaseous nitric oxide | |
AR063604A1 (es) | Atenuacion de la vasoconstriccion inducida por un portador de oxigeno vasoactivo | |
EP1962771A4 (en) | DENTAL COMPOSITIONS WITH RADIANT-IN-HEAT TRANSFORMERS AND THEIR USE | |
WO2008048514A3 (en) | Topical nitric oxide as a treatment of autoimmune diseases | |
NZ625440A (en) | Anti-cxcr1 compositions and methods | |
GB2432314B (en) | Topical medicament comprising menthol, camphor, potassium and a source of oxygen | |
MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
AU2008267058A8 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
MXPA05010402A (es) | Oxido nitrico en el tratamiento de la inflamacion. | |
UY29250A1 (es) | Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.- | |
ATE540690T1 (de) | Insulinkombinationen | |
WO2007018588A8 (en) | Stable pharmaceutical composition comprising linezolid form iv | |
NZ578065A (en) | Methods for treating psoriasis with an antibody which binds to an epitope | |
SG196863A1 (en) | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage | |
WO2009099998A3 (en) | Therapeutic treatment for lung conditions |